PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-272.88%
Both yoy net incomes decline, with AGEN at -0.85%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
77.92%
D&A growth well above AGEN's 33.07%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Deferred tax of 100.00% while AGEN is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
49.65%
SBC growth while AGEN is negative at -12.95%. John Neff would see competitor possibly controlling share issuance more tightly.
56.13%
Well above AGEN's 14.99% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.43%
Lower AP growth vs. AGEN's 180.06%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-0.47%
Negative yoy usage while AGEN is 32.07%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
85.22%
Well above AGEN's 87.02%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-64.88%
Negative yoy CFO while AGEN is 14.63%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
82.30%
CapEx growth well above AGEN's 44.13%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.30%
Investing outflow well above AGEN's 97.96%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-39.13%
We cut debt repayment yoy while AGEN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-90.34%
Both yoy lines negative, with AGEN at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.